Losartan and Atenolol Tablet
Description
LOSAROOT AT
Losartan Potassium 25 mg and Atenolol 25 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Losartan Potassium IP — 25 mg
Atenolol IP — 25 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
LOSAROOT AT is a scientifically balanced antihypertensive combination of Losartan Potassium 25 mg and Atenolol 25 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Losartan with the beta-1 selective blocking action of Atenolol, resulting in effective antihypertensive efficacy, heart rate control, and enhanced cardiovascular protection.
Losartan Potassium is an angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and provides cardiovascular and renal protection. Atenolol is a cardioselective beta-1 blocker that reduces heart rate, myocardial contractility, cardiac output, and myocardial oxygen demand, making it particularly useful in hypertensive patients with tachycardia or coronary artery disease.
LOSAROOT AT is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, ischemic heart disease, diabetes, chronic kidney disease, and patients requiring combination antihypertensive therapy with heart rate control.
Technical Knowledge of Losartan Potassium and Atenolol
Losartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. It improves vascular function and provides significant renal protection, particularly in diabetic patients.
Atenolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. This decreases myocardial oxygen demand and provides effective cardiovascular control.
The combination of Losartan and Atenolol provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits.
Mechanism of Action
Losartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues.
Atenolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained blood pressure control
Reduces heart rate and myocardial workload
Supports cardiovascular and renal protection
Improves vascular function
Effective in hypertension with tachycardia
Suitable for long-term hypertension management under medical supervision
Clinical Applications
LOSAROOT AT is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with ischemic heart disease, hypertension with diabetes mellitus, hypertension with chronic kidney disease, and long-term cardiovascular risk reduction.
Facts About Losartan Potassium and Atenolol
Losartan is a well-established ARB with proven cardiovascular and renal protective benefits. Atenolol is a cardioselective beta-blocker with extensive clinical experience in hypertension, angina, and cardiovascular disease management. The combination is widely used in patients requiring both blood pressure reduction and heart rate control with additional cardiovascular protection.
Key Facts
ARB and beta-blocker combination therapy
Losartan Potassium 25 mg for vascular and renal protection
Atenolol 25 mg for heart rate control
Provides sustained antihypertensive action
Effective in hypertension with coronary artery disease and tachycardia
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
LOSAROOT AT is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose LOSAROOT AT for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Losartan Potassium 25 mg and Atenolol 25 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
LOSAROOT AT from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Losartan Potassium and Atenolol formulation.
